StockData

CervoMed vs Alaunos Therapeutics

CRVO and TCRT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CRVO and TCRT compare

CervoMed is the larger company, worth 5.4 times as much as Alaunos Therapeutics ($22.7M against $4.2M).

Alaunos Therapeutics grew revenue faster over the last twelve months (−50.0% versus −95.7% for CervoMed).

CervoMed keeps more of each dollar of sales as profit, with a net margin of −9161% compared with −133667% at Alaunos Therapeutics.

CervoMed scores higher on the StockData Score (5 against 4 for Alaunos Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCRVOTCRT
Size and price
Market cap$22.7M$4.2M
Share price$1.50$1.66
Change, 1 year−80.5%−44.1%
Change, 5 years−94.9%−99.2%
Beta (5Y)3.41−2.45
Employees151
StockData Score
Total score5 (better)4
Valuation score1 (better)0
Growth score00
Performance score00
Health score44
Dividend score00
Valuation
P/S68.5× (better)1406×
P/B1.0× (better)6.5×
Growth
Revenue growth (TTM)−95.7%−50.0% (better)
Profitability
Operating margin−9407% (better)−135267%
Net margin−9161% (better)−133667%
Return on equity−108% (better)−186%
Return on invested capital–−489%
Financial health
Debt / equity0.000.00
Current ratio–0.77
Altman Z-score−5.50 (better)−861.74
Piotroski F-score13 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions11.6%3.6%
Held by insiders36.9%69.8%
Insider net buying, 12 months$3.0M–
Short interest, % of float12.7%24.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.